Close Menu

NEW YORK – Medicare Administrative Contractors CGS Administrators and Wisconsin Physicians Service Insurance Corporation released final coverage decisions aligning with Palmetto's limited coverage of minimal residual disease testing in patients with colorectal cancer.

The evidence review for the decisions centered specifically on Natera's Signatera test, although other ctDNA tests that meet the requirements would also be covered.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.